Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610116 | 1.00 | GFER (0.46) | GFERKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL10238015 | 0.76 | ALDH1A1 (0.40) | GFERKDM4ERAB9ASMN1; SMN2MEN1 | |
| SCHEMBL13031632 | 0.76 | GFER (0.51) | GFERKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL10238001 | 0.74 | ALDH1A1 (0.39) | GFERKDM4ERAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10237934 | 0.74 | RAB9A (0.40) | KDM4ERAB9ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL10237969 | 0.74 | SMN1; SMN2 (0.46) | KDM4ERAB9ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL3592969 | 0.73 | GFER (0.49) | GFERKDM4ERAB9ASMN1; SMN2LMNA | |
| SCHEMBL16215992 | 0.71 | HRH3 (0.41) | KDM4ERAB9ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL10237937 | 0.71 | HRH3 (0.41) | KDM4ERAB9ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL608047 | 0.71 | HRH3 (0.41) | KDM4ERAB9ASMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176222-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2014-11-05 | — | — | EP | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-20120040826-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040826-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040826-A1 | NOVEL HERBICIDES | DDT, HDHD5, DDC | GFER 1053/4885KDM4E 1609/4885RAB9A 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.